Esomeprazole in the treatment of patients with heartburn and other upper gastrointestinal symptoms, referred to primary care - Results of the inpractice evaluation program in Romania

Romanian Journal of Gastroenterology

Volumn 14, Issue 1, 2005, Pages 9-14

  Diculescu, Mircea ^a,d   Iacob, Rǎzvan ^a   Chira, Constantin ^b   Mihǎilǎ, Doina ^c   Iacob, Speranta ^a  

^a FUNDENI CLINICAL INSTITUTE   (Romania)

^b Clinical Hospital Dimitrie Gerota   (Romania)

^c Family Medicine Department   (Romania)

^d NONE   (Romania)

Author keywords

Esomeprazole; Gastroesophageal reflux disease; Heartburn; Primary care

Indexed keywords

ANTACID AGENT; ESOMEPRAZOLE; HISTAMINE H2 RECEPTOR ANTAGONIST; PROKINETIC AGENT; PROTON PUMP INHIBITOR;

ABDOMINAL PAIN; ADULT; AGED; ARTICLE; CLINICAL PRACTICE; DISEASE SEVERITY; EVALUATION; FEMALE; FOLLOW UP; GASTROESOPHAGEAL REFLUX; GASTROINTESTINAL SYMPTOM; GEOGRAPHIC DISTRIBUTION; HEALTH PROGRAM; HEARTBURN; HUMAN; INTERNAL MEDICINE; MAJOR CLINICAL STUDY; MALE; MEDICAL SPECIALIST; OUTCOMES RESEARCH; PRESCRIPTION; PRIMARY MEDICAL CARE; ROMANIA; SYMPTOMATOLOGY;

EID: 16244403016     PISSN: 12214167     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (21)

1. Diculescu M, Piţigoi D. Sindromul Barrett - de la boala de reflux gastroesofagian la adenocarcinomul esofagian. Bucharest, Ed. Cartea Universitarǎ, 2004
2. Gheorghe L, Gheorghe C. Boala de reflux gastroesofagian. In: Vademecum în gastroenterologie. Bucharest, Ed. Nemira 2002: 13-21
3. Achem SR. Endoscopy-negative gastroesophageal reflux disease: the hypersensitive esophagus. Gastroenterol Clin North Am 1999; 28:893-904
4. Carlsson R, Dent J, Bolling-Sternevald E et al. The usefulness of a structured questionnaire in the assessment of symptomatic gastroesophageal reflux disease. Scand J Gastroenterol 1998;33:1023-1029
5. Ramakrishnan A, Katz PO. Pharmacologic management of gastroesophageal reflux disease. Curr Gastroenterol Rep 2002;4:218-224
6. Kahrilas PJ, Pandolfino JE. Gastroesophageal reflux disease and its complications, including Barrett's metaplasia. In:Feldman M, Scharschmidt BF, Sleisenger MH. Sleisenger & Fordtran's Gastrointestinal and Liver Disease. Philadelphia: WB Saunders Co 2002:599-622
7. Fass R, Fennerty MB, Vakil N. Nonerosive reflux disease - current concepts and dilemmas. Am J Gastroenterol 2001;96:303-314
8. Baker DE. Esomeprazole: update and clinical review. Rev Gastroenterol Disord 2002; 2:189-199
9. Walt RP, Male PJ, Rawlings J et al. Comparison of the effect of ranitidine, cimetidine and placebo on the 24-hour intragastric acidity and nocturnal acid secretion in patients with duodenal ulcer. Gut 1981; 22: 49-54
10. Sharma BK, Walt RP, Pounder RE et al. Optimal dose of oral omeprazole for maximal 24-hour decrease of intragastric acidity. Gut 1984; 25: 957-964
11. Johnsson F, Hatlebakk JG, Klintenberg AC, Roman J. Symptom-relieving effect of esomeprazole 40 mg daily in patients with heartburn. Scand J Gastroenterol 2003; 38:347-353
12. Kahrilas PJ, Fennerty MB, Joelsson B. High- versus standard-dose ranitidine for control of heartburn in poorly responsive acid reflux disease: a prospective, controlled trial. Am J Gastroenterol 1999;94:92-97
13. Kulig M, Leodolter A, Vieth M et al. Quality of life in relation to symptoms in patients with gastro-oesophageal reflux disease - an analysis based on the ProGERD initiative. Aliment Pharmacol Ther 2003: 15;18:767-776
14. Miner PJr, Katz PO, Chen Y, Sostek M. Gastric acid control with esomeprazole, lansoprazole, omeprazole, pantoprazole, and rabeprazole: a five-way crossover study. Am J Gastroenterol 2003;98:2616-2620
15. Talley NJ, Lauritsen K, Tunturi-Hihnala H et al. Esomeprazole 20 mg maintains symptom control in endoscopy-negative gastro-oesophageal reflux disease: a controlled trial of 'on-demand' therapy for 6 months. Aliment Pharmacol Ther 2001;15:347-354
16. Hatlebakk JG. Review article: gastric acidity-comparison of esomeprazole with other proton pump inhibitors. Aliment Pharmacol Ther 2003;17 Suppl 1:10-15; discussion 16-17
17. Vakil NB, Shaker R, Johnson DA et al. The new proton pump inhibitor esomeprazole is effective as a maintenance therapy in GERD patients with healed erosive oesophagitis: a 6-month, randomized, double-blind, placebo-controlled study of efficacy and safety. Aliment Pharmacol Ther 2001;15:927-935
18. Johnson DA, Benjamin SB, Vakil NB et al. Esomeprazole once daily for 6 months is effective therapy for maintaining healed erosive esophagitis and for controlling gastroesophageal reflux disease symptoms: a randomized, double-blind, placebo-controlled study of efficacy and safety. Am J Gastroenterol 2001;96:27-34
19. Wahlqvist P, Junghard O, Higgins A, Green J. Cost effectiveness of proton pump inhibitors in gastro-oesophageal reflux disease without oesophagitis: comparison of on-demand esomeprazole with conventional omeprazole strategies. Pharmacoeconomics 2002;20:267-277
20. Richter JE, Kahrilas PJ, Johanson J et al. Efficacy and safety of esomeprazole compared with omeprazole in GERD patients with erosive esophagitis: a randomized controlled trial. Am J Gastroenterol 2001;96:656-665
21. Kahrilas PJ, Falk GW, Johnson DA et al. Esomeprazole improves healing and symptom resolution as compared with omeprazole in reflux oesophagitis patients: a randomized controlled trial. The Esomeprazole Study Investigators. Aliment Pharmacol Ther 2000;14:1249-1258